Company Description
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions.
It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.
The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.
It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.
Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Country | Israel |
Founded | 2001 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 123 |
CEO | Yaacov Yanay |
Contact Details
Address: Matam Advanced Technology Park, Building No. 5 Haifa, L3 3508409 Israel | |
Phone | 972-74-710-7171 |
Website | pluri-biotech.com |
Stock Details
Ticker Symbol | PLUR |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001158780 |
CUSIP Number | 72942G104 |
ISIN Number | US72942G1040 |
Employer ID | 98-0351734 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Yaacov Yanay | President, Chief Executive Officer and Director |
Chen Franco-Yehuda | Chief Financial Officer, Treasurer and Secretary |
Lior Raviv | Chief Technology Officer |
Efrat Livne-Hadass | Vice President of Human Resources |
Dr. Nitsan Halevy M.D. | Chief Medical Officer |
Nimrod Bar Zvi | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 2, 2024 | 8-K | Current Report |
Jun 26, 2024 | 8-K | Current Report |
Jun 18, 2024 | 8-K | Current Report |
May 31, 2024 | 8-K | Current Report |
May 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 9, 2024 | 10-Q | Quarterly Report |
May 1, 2024 | ARS | Filing |
May 1, 2024 | DEF 14A | Other definitive proxy statements |
Apr 17, 2024 | 8-K | Current Report |